USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Galvani Bioelectronics Limited

USPTO PatentsView assignee record - 65 granted patents across 15 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

13.9

Avg claims per patent

+3050%

5-year filing velocity

The verdict

Galvani holds 65 US patents across 15 technology areas, rank #5,282 of 50,000 tracked assignees.

#5,282
of 50,000 US assignees by volume: Top 6%
by Innovation Score (56.5/100): 13.9
avg claims per patent: +3050%
filing velocity, last 5 yrs

Portfolio overview

Galvani Bioelectronics Limited has been granted 65 US utility patents between 2019 and 2025, placing Galvani Bioelectronics Limited at rank #5,282 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.9 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a Foreign Corporation, Galvani Bioelectronics Limited is one of the more focused assignees in the PatentsView dataset. By volume, Galvani sits between Envision AESC Japan Ltd. (65 patents, rank #5,278) and Hisense Co., Ltd. (65 patents, rank #5,286) - the closest US assignees by grant volume. The composite Innovation Score of 56.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 63 grants, compared with 2 in the 2015–2019 window, a +3050% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Galvani Bioelectronics Limited's 13.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Galvani Bioelectronics Limited against peers pursuing similar technology classes.

Envision AESC Jap…

65
Evapco

65
FUJI SEAL Interna…

65
Foxlink Image Tec…

65
Graco Children's…

65
Gachon University…

65
Glaukos

65
Hisense

65
Galvani Bioelectr… ◀

65

What this shows Galvani holds 65 patents at rank #5,282, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Galvani

By rank, the assignees closest to #5,282 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Galvani's primary technology class.

Galvani's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

57 Top 6% higher than 94% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Galvani Bioelectronics Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	2	3.1%
2020	2	3.1%
2021	8	12.3%
2022	13	20.0%
2023	23	35.4%
2024	13	20.0%
2025	4	6.2%

Which technologies does Galvani Bioelectronics Limited patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 51

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 28

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 4

B29C - SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING 2

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 2

H04B - TRANSMISSION 2

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 2

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 2

H02J - CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY 2

B29L - INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES 1

B29K - INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR ; MOULDS, ; REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS 1

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 1

G21H - OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION 1

H02H - EMERGENCY PROTECTIVE CIRCUIT ARRANGEMENTS 1

G01R - MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES 1

Top 15 of 15 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Accelerating

Where it ranks

Overall rank by patents

#5,282

Across all tracked assignees

Innovation Score

56.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Galvani Bioelectronics Limited hold?

Galvani Bioelectronics Limited holds 65 US granted patents filed between 2019 and 2025, spanning 15 technology areas.

What is Galvani Bioelectronics Limited's Innovation Score?

Galvani Bioelectronics Limited has an Innovation Score of 56.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Galvani Bioelectronics Limited focus on?

Galvani Bioelectronics Limited's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 51 patents. The company has filed patents in 15 CPC subclasses total.

Is Galvani Bioelectronics Limited's patent filing rate increasing or decreasing?

Galvani Bioelectronics Limited's recent filing velocity is +3050% compared to the prior five-year period. This indicates accelerating innovation.

What does claim depth mean for Galvani Bioelectronics Limited's patents?

Galvani Bioelectronics Limited's patents average 13.9 claims each. This falls within the standard range, providing solid legal coverage.

How is the Galvani Bioelectronics Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Galvani's 65 grants land it in the top 6% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Galvani ranks #5,282 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.